Month: October 2022

Top Line: Has anyone not been inundated with incendiary one-liners on results from the NordICC trial? The Study: Spoiler alert:…

Most folks were left confused after a recent Alliance trial reported significantly worse (and just overall bad) local control with…

Headline: Single-fraction celiac plexus radiosurgery for complex pain arising from adjacent gastrointestinal or retroperitoneal malignancies works. The Study: Kudos to…

Headline: We now have phase 3 data comparing stereotactic body radiation (SBRT) to hypofractionated radiation (HFRT) for stage I non-small…

Headline: Artificial intelligence using digital histopathology provides better prognostication than NCCN risk categories for men with localized prostate cancer. The…

The phase 3 CALLA trial revealed no indication of benefit with the addition of durvalumab to standard definitive chemoradiation for…

Headline: Consolidative ablative radiation for oligoprogressive non-small cell lung cancer (NSCLC) corresponds to a 4-fold benefit in progression-free survival with…

Outcomes at 7 years from the PCS5 trial show noninferior overall survival, prostate cancer mortality, and biochemical recurrence when using…

Headline: Concurrent lumpectomy boost results in noninferior local control and similar cosmesis when compared to the tried and true sequential…

Headline: The PD-L1 inhibitor durvalumab is not an appropriate substitute for patients warranting definitive chemoradiation to the head and neck…